Inventaire - your friends and communities are your best library - Inventaire

Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade

author

Heidi Barth

published in: World Journal of Hepatology

date of publication: 2015-04-01

main subject: Hepatitis C virus, hepatitis C

Cites articles 102

Date

Title

Authors

2015-02-09

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

Bryony Simmons, Saye Khoo
2015-01-05

Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses

Paul Becher, Markus H Heim, Jessika M.V. Cavalleri, Richard Brown, Alexander Postel, Thomas Pietschmann, Eike Steinmann
2014-11-11

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

Edward Tam, Martin Lagging, Laurent Alric, Luis A Balart
2014-11-11

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

Nina Weis, Stanislas Pol, Mark Sulkowski, Jan Gerstoft
2014-11-28

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies

Thierry Verbinnen, Leen Vijgen
2014-11-01

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

Joannah R Fergusson, Leo Swadling, Stefania Capone, Evan W Newell, Paul Klenerman, Anthony Brown
2014-11-20

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
2014-09-01

Daclatasvir + asunaprevir: first global approval
2014-07-28

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Sivi Ouwerkerk-Mahadevan, Mark Sulkowski
2014-07-28

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Jia-Horng Kao, Guido Gerken, Stanislas Pol, Patrick Marcellin
2014-07-28

Global distribution and prevalence of hepatitis C virus genotypes

Oliver G. Pybus, Graham Cooke, Eleanor J. Barnes, Jane P Messina, Abraham D Flaxman, Anthony Brown
2014-07-15

Recurrent HCV after liver transplantation-mechanisms, assessment and therapy
2014-07-08

Trace amounts of sporadically reappearing HCV RNA can cause infection

Damien C Tully, Barbara Rehermann
2014-07-06

A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity

Luke W Koblan, Todd Golub
2014-06-16

Protective immunity against hepatitis C: many shades of gray

Mohamed Abdel Hakeem, Naglaa H Shoukry
2014-06-06

Update on hepatitis C virus resistance to direct-acting antiviral agents

Eva Poveda, David L Wyles
2014-06-04

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Antonio Craxì, Sivi Ouwerkerk-Mahadevan, Maria Beumont-Mauviel, Larysa Moroz, Gregory J Dore
2014-06-04

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Sivi Ouwerkerk-Mahadevan, Maria Beumont-Mauviel, Fred Poordad, Patrick Marcellin, Maria Buti, Ewa Janczewska
2014-05-21

Resistance to hepatitis C virus protease inhibitors
2014-05-04

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

K. Rajender Reddy, Ewa Janczewska
2014-04-12

Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?
2014-05-15

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
2014-04-17

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

K. Rajender Reddy, Mark Sulkowski
2014-05-15

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

K. Rajender Reddy
2014-03-16

Development and function of human innate immune cells in a humanized mouse model

Sofia V Gearty, Till Strowig, Yasuyuki Saito, Markus G Manz, Tim Willinger, Karolina Palucka, Richard Flavell, Anthony Rongvaux, Lino L Teichmann, Florentina Marches, Stephanie Halene
2014-03-12

New hepatitis C therapies: the toolbox, strategies, and challenges

Jean-Michel Pawlotsky
2014-03-03

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial

Stefan Zeuzem, Sivi Ouwerkerk-Mahadevan, Maria Beumont-Mauviel, Pietro Andreone, Andrzej Horban
2014-02-26

The past, present and future of neutralizing antibodies for hepatitis C virus

Jane A. McKeating, Alexander W. Tarr, Jonathan Ball
2014-05-15

Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2

Samantha A Yost, Joshy Jacob
2014-01-16

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

K. Rajender Reddy, Mark Sulkowski
2014-01-06

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries

Bryony Simmons
2014-01-28

Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees

Article - wd:Q35501190

Welcome to Inventaire

the library of your friends and communities

you are offline